BioSymetrics Collaborates with Janssen and Sema4 to Predict the Onset of COVID-19

As part of the collaboration, the parties will use BioSymetrics’ Contingent-AI™ engine across several projects to characterize high-risk populations, measure and predict disease progression based on biological risk factors and treatment course, and identify markers for clinical phenotype and severity of disease.

Read More

Uniting Against COVID-19

Already working with clinicians, leveraging international collaborations to put prediction platforms in place, and re-investigating our drug lead pipeline, BioSymetrics will pursue any collaboration to have a positive impact against COVID and support the heroes working tirelessly in the hospitals and clinics around the world.

Read More

De-noising CMap L1000 Data

As with any assay, L1000 data is noisy. Experimental replicates (the same compound tested on the same cell line under the same conditions) often result in different levels of expression being measured. The process of de-noising the L1000 data makes it easier to see true assay response, and pick a representative concentration for each compound.

Read More